Raymond James raises Dianthus Therapeutics target to $134
The target suggests substantial upside, though a single analyst forecast without stated rationale warrants limited confidence.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The target suggests substantial upside, though a single analyst forecast without stated rationale warrants limited confidence.
What happened, with direct paths to the underlying reporting
Raymond James raised its DNTH price target to $134, about 56% above the posted price of $85.81. The record provides no supporting rationale.
Target: $134
Posted price: $85.81
Analyst firm: Raymond James
Analyst: Ryan Deschner
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.